Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + sintilimab
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Disitamab vedotin + sintilimab is a combination therapy consisting of a HER2-targeted antibody-drug conjugate (disitamab vedotin) and a PD-1 inhibitor (sintilimab). Disitamab vedotin comprises a novel HER2-directed monoclonal antibody (hertuzumab) coupled with monomethyl auristatin E (MMAE) via a cleavable valine-citrulline linker. MMAE is an antimitotic agent that blocks tubulin polymerization, resulting in cell cycle arrest and apoptosis. Sintilimab is a PD-1 inhibitor that enhances T-cell immune responses against cancer cells. This combination is being investigated for HER2-expressing unresectable gastric cancer and gastroesophageal junction adenocarcinoma.
- Brand names
- Aidixi + sintilimab
- Other names
- RC48-ADC + sintilimabdisitamab vedotin + PD-1 inhibitor
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + sintilimab.